Biopharmaceutical firm secures PIPE funding through legal consultation by Dechert
vTv Therapeutics Secures $80 Million in Financing for Type 1 Diabetes and Other Conditions
vTv Therapeutics, a late-stage biopharmaceutical company based in High Point, North Carolina, has secured $80 million in financing through a private placement in public equity (PIPE) deal, as announced on September 5, 2025.
The financing was led by Evercore ISI and TD Cowen as lead placement agents, with international law firm Dechert advising the company. The Dechert advisory team was led by corporate and life sciences partner David S Rosenthal, and included associates Taylor Stevens, Anjanaye Jariwala, and Abigail T Ferraioli.
The financing will support the development of therapies to treat type 1 diabetes and other conditions. vTv Therapeutics' clinical pipeline is led by the potential first-in-class, novel oral adjunctive therapy to insulin, cadisegliatin. This drug is currently in Phase 3 trials for the treatment of type 1 diabetes, with the CATT1 trial evaluating its potential to reduce the frequency of level 2 and 3 hypoglycemic events and improve glycemic control in people with type 1 diabetes.
Elizabeth Mily, CEO of the T1D Fund, expressed support for vTv Therapeutics and the advancement of cadisegliatin through the CATT1 Phase 3 trial for people with type 1 diabetes. Paul Sekhri, vTv Therapeutics' chairman, president, and CEO, commented on the financing, stating it will enable the advancement of cadisegliatin in the CATT1 trial.
Samsara BioCapital, LP and the T1D Fund will participate in the financing, along with new investors Invus and Trails Edge Capital Partners. The financing is expected to provide additional runway for vTv Therapeutics following topline data from the CATT1 study, which is expected in the second half of 2026.
Paul Sekhri, the CEO of vTv Therapeutics, secured $80 million in funding in September 2025 to support therapy development for type 1 diabetes and other conditions. vTv Therapeutics specializes in the development of oral, small molecule drug candidates for the treatment and management of diabetes and other chronic diseases.
The financing was due to close around September 3, subject to the satisfaction of customary closing conditions. The specific terms of the financing were not disclosed in the provided information.
Read also:
- Recognition of Exceptional Patient Care: Top Staff Honored by Medical Center Board
- A continuous command instructing an entity to halts all actions, repeated numerous times.
- Oxidative Stress in Sperm Abnormalities: Impact of Reactive Oxygen Species (ROS) on Sperm Harm
- Is it possible to receive the hepatitis B vaccine more than once?
